BLUE BELL, Pa., Feb. 28, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that Inovio management will present an overview of the company at investment conferences hosted by Cowen Group and ROTH Capital Partners.
Cowen 32nd Annual Health Care Conference March 5-7 Boston, MA110 Huntington Ave, The Boston Marriott Copley Place
Inovio Presentation Monday, March 5 3:30 - 4:00 p.m. EST J. Joseph Kim, PhD, President and CEO
A live and archived webcast of the presentation will be accessible on Inovio's website at http://www.inovio.com/ROTH 24th Annual Conference March 11-14 Dana Point, CA1 Ritz Carlton Dr, The Ritz Carlton Inovio Presentation Wednesday, March 14 11:30 - 12:00 p.m. PST Peter Kies, CFO About Inovio Pharmaceuticals, Inc. Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com. * * *